JOE
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Journal of Endocrinology (1982) 93, 41-46    DOI: 10.1677/joe.0.0930041
© 1982 Society for Endocrinology

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitzgerald, B. P.
Right arrow Articles by Cunningham, F. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Fitzgerald, B. P.
Right arrow Articles by Cunningham, F. J.

Effects of metoclopramide and bromocriptine on prolactin secretion in the pregnant ewe

B. P. Fitzgerald and F. J. Cunningham

Metoclopramide and bromocriptine, drugs which are respectively antagonistic and agonistic to dopamine receptor activity, were used to investigate the control of prolactin secretion in the ewe during pregnancy. Normal concentrations of prolactin were found during pregnancy, i.e. values were low and stable during the first 100 days but thereafter increased progressively to reach maximum values at day 140. Treatment with bromocriptine suppressed levels to undetectable values (< 1·4 µg/l plasma) between days 40 and 100 of pregnancy. Later in gestation, however, bromocriptine administered between days 120 and 140 was less effective, indicating that the pituitary gland was less responsive to the same degree of inhibition. Treatment with metoclopramide alone provoked a progressively greater release of prolactin as pregnancy advanced whereas in bromocriptine-treated animals an associated release of prolactin in response to metoclopramide was seen only between days 120 and 140 of pregnancy.

These results are interpreted as evidence that the raised concentrations of prolactin characteristic of late pregnancy in the ewe are due to a reduced responsiveness of the pituitary gland to inhibitory stimuli, or to a decreased secretion of endogenous dopamine into the hypophysial portal blood system or to both.







HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1982 by the Society for Endocrinology.